Zacks Investment Research upgraded shares of ReWalk Robotics Ltd (NASDAQ:RWLK) from a hold rating to a buy rating in a research report released on Thursday morning. The brokerage currently has $1.50 price target on the medical device company’s stock.

According to Zacks, “ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The Company’s exoskeletons allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It offers ReWalk Personal for everyday use to individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy to individuals with lower limb disabilities in the clinical rehabilitation environment. ReWalk Robotics Ltd. is headquartered in Yokneam Ilit, Israel. “

Other equities research analysts have also issued reports about the stock. Canaccord Genuity reaffirmed a buy rating and set a $3.00 price target on shares of ReWalk Robotics in a report on Monday, November 6th. Oppenheimer Holdings, Inc. set a $4.00 price target on shares of ReWalk Robotics and gave the company a buy rating in a report on Friday, August 4th. Finally, Jefferies Group LLC lowered their price target on shares of ReWalk Robotics from $8.00 to $5.00 and set a buy rating for the company in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $3.00.

ReWalk Robotics (NASDAQ:RWLK) remained flat at $$1.37 during trading on Thursday. The company’s stock had a trading volume of 110,700 shares, compared to its average volume of 346,555. ReWalk Robotics has a twelve month low of $1.10 and a twelve month high of $3.60. The company has a quick ratio of 1.65, a current ratio of 2.02 and a debt-to-equity ratio of 7.46.

ReWalk Robotics (NASDAQ:RWLK) last released its quarterly earnings data on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.10. ReWalk Robotics had a negative net margin of 346.14% and a negative return on equity of 568.25%. The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $1.63 million. During the same quarter in the prior year, the business earned ($0.62) earnings per share. The business’s quarterly revenue was up 21.4% compared to the same quarter last year. research analysts forecast that ReWalk Robotics will post -1.14 EPS for the current fiscal year.

WARNING: “ReWalk Robotics Ltd (RWLK) Lifted to “Buy” at Zacks Investment Research” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/13/rewalk-robotics-ltd-rwlk-lifted-to-buy-at-zacks-investment-research.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. grew its holdings in ReWalk Robotics by 1,495.6% during the 3rd quarter. Advisor Group Inc. now owns 181,900 shares of the medical device company’s stock valued at $264,000 after purchasing an additional 170,500 shares in the last quarter. Essex Investment Management Co. LLC grew its holdings in ReWalk Robotics by 328.7% during the 3rd quarter. Essex Investment Management Co. LLC now owns 156,981 shares of the medical device company’s stock valued at $228,000 after purchasing an additional 120,362 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in ReWalk Robotics by 61.7% during the 1st quarter. Renaissance Technologies LLC now owns 78,600 shares of the medical device company’s stock valued at $165,000 after purchasing an additional 30,000 shares in the last quarter. 4.62% of the stock is owned by institutional investors and hedge funds.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.

Get a free copy of the Zacks research report on ReWalk Robotics (RWLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.